Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel to vote on von Eschenbach

This article was originally published in The Gray Sheet

Executive Summary

Senate Health Education Labor & Pensions Committee schedules Sept. 20 vote on nomination of Andrew von Eschenbach to be permanent FDA commissioner despite the prospect of future holds. Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.) have threatened to place holds on the nomination once it reaches the Senate floor due to the lack of a drug importation program and continued marketing of Danco Laboratories' abortion pill Mifeprex (mifepristone), respectively. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) only recently released their hold on the nominee following FDA's approval of Plan B for dual Rx/OTC status (1"The Gray Sheet" Aug. 28, 2006, In Brief)...

You may also be interested in...

Von Eschenbach Nomination Clears Committee But Faces Hurdles On Floor

The Senate Health, Education, Labor & Pensions (HELP) Committee approved the nomination of FDA Acting Commissioner Andrew von Eschenbach as permanent commissioner and sent the nomination to the Senate floor Sept. 20

Von Eschenbach nomination on track?

Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) drop their hold on Acting FDA Commissioner Andrew von Eschenbach's nomination to the permanent post Aug. 24 following the agency's decision to make Barr Pharmaceuticals' Plan B emergency contraceptive available over-the-counter for women age 18 and older (1"The Gray Sheet" Aug. 7, 2006, p. 17). However, at least one Republican is said to be considering a hold in opposition to the Plan B decision, according to a Senate Health, Education, Labor & Pensions Committee staffer. Committee Chair Michael Enzi (R-Wyo.) has not yet scheduled a vote on the nominee, the staffer says. Enzi is reviewing the approval decision and gauging committee members' reactions to it...

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts